Inventiva Stock Forum

$Inventiva (IVA.US)$
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
Wednesday, 26th February at 4:00 pm
• The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and prehepatic non-fibrotic PH
• Lanifibranor was observed to decrease portal pressure by improving Liver Sinusoidal Endothelial Cell (LSEC) dysfun...

$Inventiva (IVA.US)$
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Thursday, 20th February at 4:00 pm
• Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 study
• Positive results could support the initiation of a pivotal Phase 3 trial in patients in Japan with MASH
• The study represents...

$Inventiva (IVA.US)$
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology
Wednesday, 29th January at 4:00 pm
• As previously reported1, the study met the primary efficacy endpoint for the treatment with lanifibranor 800mg demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of t...

$Inventiva (IVA.US)$
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
Wednesday, 22nd January at 4:00 pm
Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfu...

$Inventiva (IVA.US)$
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
Monday, 16th December at 2:30 am
◦ Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024.
 
◦ Proceeds from the completed first tranche to be primarily used to advance Inventiva's ...

$Inventiva (IVA.US)$ Inventiva Announces The Recommendation Of The Fifth DMC Of The NATiV3 Phase 3 Clinical Trial With Lanifibranor In Patients With MASH
Benzinga· 3 mins ago
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.
The recommendation was based on the unblinded review by the DMC of safety data from more than 1000 patients randomized in the main and exploratory cohorts,...

$Inventiva (IVA.US)$https://www.moomoo.com/news/notice/301091081?ns_stock_id=79237851862280&client_hour_clock=24&main_broker=WwogIDEwMDgKXQ%3D%3D&sg_cid=103382313&skintype=1&jp_cid=103382313&futusource=news_stock_stockpagenews&level=0&global_content=%7B%22promote_content%22%3A%22mm%3Anotice%3A301091081%22%2C%22invite%22%3A103382313%7D&data_ticket=1725015159622121
Big buyout of the stocks?